S&P 500   4,570.56 (+0.56%)
DOW   35,766.86 (+0.25%)
QQQ   377.94 (+1.03%)
AAPL   148.92 (+0.15%)
MSFT   308.46 (-0.23%)
FB   325.56 (+0.29%)
GOOGL   2,745.03 (-0.23%)
TSLA   1,009.52 (+10.98%)
AMZN   3,326.59 (-0.27%)
NVDA   233.11 (+2.57%)
BABA   176.13 (-0.88%)
NIO   41.15 (+5.84%)
CGC   13.36 (-0.15%)
GE   105.63 (+1.52%)
AMD   122.90 (+2.57%)
MU   69.03 (+2.25%)
T   25.45 (-0.16%)
F   15.98 (-1.84%)
ACB   7.15 (+1.13%)
DIS   172.36 (+1.74%)
PFE   42.99 (-0.39%)
BA   212.78 (-0.09%)
AMC   37.20 (+1.64%)
S&P 500   4,570.56 (+0.56%)
DOW   35,766.86 (+0.25%)
QQQ   377.94 (+1.03%)
AAPL   148.92 (+0.15%)
MSFT   308.46 (-0.23%)
FB   325.56 (+0.29%)
GOOGL   2,745.03 (-0.23%)
TSLA   1,009.52 (+10.98%)
AMZN   3,326.59 (-0.27%)
NVDA   233.11 (+2.57%)
BABA   176.13 (-0.88%)
NIO   41.15 (+5.84%)
CGC   13.36 (-0.15%)
GE   105.63 (+1.52%)
AMD   122.90 (+2.57%)
MU   69.03 (+2.25%)
T   25.45 (-0.16%)
F   15.98 (-1.84%)
ACB   7.15 (+1.13%)
DIS   172.36 (+1.74%)
PFE   42.99 (-0.39%)
BA   212.78 (-0.09%)
AMC   37.20 (+1.64%)
S&P 500   4,570.56 (+0.56%)
DOW   35,766.86 (+0.25%)
QQQ   377.94 (+1.03%)
AAPL   148.92 (+0.15%)
MSFT   308.46 (-0.23%)
FB   325.56 (+0.29%)
GOOGL   2,745.03 (-0.23%)
TSLA   1,009.52 (+10.98%)
AMZN   3,326.59 (-0.27%)
NVDA   233.11 (+2.57%)
BABA   176.13 (-0.88%)
NIO   41.15 (+5.84%)
CGC   13.36 (-0.15%)
GE   105.63 (+1.52%)
AMD   122.90 (+2.57%)
MU   69.03 (+2.25%)
T   25.45 (-0.16%)
F   15.98 (-1.84%)
ACB   7.15 (+1.13%)
DIS   172.36 (+1.74%)
PFE   42.99 (-0.39%)
BA   212.78 (-0.09%)
AMC   37.20 (+1.64%)
S&P 500   4,570.56 (+0.56%)
DOW   35,766.86 (+0.25%)
QQQ   377.94 (+1.03%)
AAPL   148.92 (+0.15%)
MSFT   308.46 (-0.23%)
FB   325.56 (+0.29%)
GOOGL   2,745.03 (-0.23%)
TSLA   1,009.52 (+10.98%)
AMZN   3,326.59 (-0.27%)
NVDA   233.11 (+2.57%)
BABA   176.13 (-0.88%)
NIO   41.15 (+5.84%)
CGC   13.36 (-0.15%)
GE   105.63 (+1.52%)
AMD   122.90 (+2.57%)
MU   69.03 (+2.25%)
T   25.45 (-0.16%)
F   15.98 (-1.84%)
ACB   7.15 (+1.13%)
DIS   172.36 (+1.74%)
PFE   42.99 (-0.39%)
BA   212.78 (-0.09%)
AMC   37.20 (+1.64%)
NASDAQ:RNAZ

TransCode Therapeutics Short Interest Ratio and Short Volume

$2.74
-0.01 (-0.36 %)
(As of 10/25/2021 02:10 PM ET)
Add
Compare
Today's Range
$2.71
$2.77
50-Day Range
$2.37
$4.02
52-Week Range
$2.35
$7.00
Volume1,546 shs
Average Volume3.91 million shs
Market Capitalization$35.36 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

TransCode Therapeutics (NASDAQ:RNAZ) Short Interest Data

Current Short Volume455,400 shares
Previous Short Volume31,400 shares
Change Vs. Previous Month+1,350.32%
Dollar Volume Sold Short$1.36 million
Short Interest Ratio / Days to Cover0.1
Last Record DateSeptember, 30 2021
Outstanding Shares12,905,000 shares
Float Size7,150,000 shares
Short Percent of Float6.37%
Today's Trading Volume1,546 shares
Average Trading Volume3,905,227 shares
Today's Volume Vs. Average-99.96%

Days to Cover Over Time

Percentage of Float Shorted Over Time

cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling TransCode Therapeutics ?

Sign up to receive the latest short interest report for TransCode Therapeutics and its competitors with MarketBeat's FREE newsletter.

TransCode Therapeutics (NASDAQ:RNAZ) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
9/30/2021455,400 shares $1.36 million +1,350.3%6.4%0.1 $2.99
9/15/202131,400 shares $81,012.00 -39.7%0.4%0 $2.58
8/31/202152,100 shares $158,384.00 +128.5%0.7%0 $3.04
8/13/202122,800 shares $65,436.00 No Change0.4%0 $2.87

TransCode Therapeutics (NASDAQ:RNAZ) Short Interest FAQ













TransCode Therapeutics (NASDAQ:RNAZ) Short Interest Frequently Asked Questions

What is TransCode Therapeutics' current short interest?

Short interest is the volume of TransCode Therapeutics shares that have been sold short but have not yet been covered or closed out. As of September 30th, investors have sold 455,400 shares of RNAZ short. 6.37% of TransCode Therapeutics' shares are currently sold short. Learn More on TransCode Therapeutics' current short interest.

What is a good short interest percentage for TransCode Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.37% of TransCode Therapeutics' floating shares are currently sold short.

Is TransCode Therapeutics' short interest increasing or decreasing?

TransCode Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totaling 455,400 shares, an increase of 1,350.3% from the previous total of 31,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is TransCode Therapeutics' float size?

TransCode Therapeutics currently has issued a total of 12,905,000 shares. Some of TransCode Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. TransCode Therapeutics currently has a public float of 7,150,000 shares.

How does TransCode Therapeutics' short interest compare to its competitors?

6.37% of TransCode Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to TransCode Therapeutics: Orphazyme A/S (0.00%), Assembly Biosciences, Inc. (0.00%), Qilian International Holding Group Limited (0.00%), Synlogic, Inc. (1.40%), SELLAS Life Sciences Group, Inc. (0.00%), BioVie Inc. (6.23%), Savara Inc (2.29%), Eton Pharmaceuticals, Inc. (3.55%), Heat Biologics, Inc. (8.80%), and BioLineRx Ltd. (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: S&P Global Inc. ($7.35 billion), Advanced Micro Devices, Inc. ($6.43 billion), Charter Communications, Inc. ($5.68 billion), Wayfair Inc. ($4.48 billion), Uber Technologies, Inc. ($3.77 billion), Canadian Pacific Railway Limited ($3.73 billion), Palo Alto Networks, Inc. ($3.10 billion), Zoom Video Communications, Inc. ($2.87 billion), Match Group, Inc. ($2.83 billion), and DoorDash, Inc. ($2.54 billion). View all of the most shorted stocks.

What does it mean to sell short TransCode Therapeutics stock?

Short selling RNAZ is an investing strategy that aims to generate trading profit from TransCode Therapeutics as its price is falling. TransCode Therapeutics' stock is trading down $0.01 today. To short TransCode Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that TransCode Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against TransCode Therapeutics?

A short squeeze for TransCode Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of RNAZ, which in turn drives the price of the stock up even further.

How often is TransCode Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RNAZ, twice per month. The most recent reporting period available is September, 30 2021.



This page was last updated on 10/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.